VANCOUVER, BC, March 3, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a leader in the development of psilocybin and other entheogens, is pleased to announce the launch of its US-based Observational Study NM-101: “Microbiotic Diversity in Autism Spectrum Disorder (ASD): Improving Diagnostics by Differentiating Subtypes.


Previous articleAwakn Announces Exclusive License Deal with the University of Exeter to Commercialise the ‘Ketamine in the Reduction of Alcoholic Relapse’ (KARE) Intervention Validated in a Phase II Clinical Trial
Next articleBetterLife Engages Eurofins CDMO for Next Generation Psychedelic TD-0148A Manufacturing